The paradox of histone deacetylase inhibitor-mediated modulation of cellular responses to radiation

被引:33
作者
Karagiannis, TC
El-Osta, A
机构
[1] Baker Med Res Inst, AMREP, Epigenet Human Hlth & Dis Lab, Prahran, Vic 3181, Australia
[2] Peter MacCallum Canc Ctr, Trescowthick Res Labs, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
histone acetylation; histone deacetylase; chromatin remodelling; HDAC inhibitor; radiosensitivity; radioprotector;
D O I
10.4161/cc.5.3.2421
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Given the widespread use of radiotherapy in cancer, there has been a longstanding interest in the development of chemical compounds that can modify cellular responses to ionizing radiation. Additionally, recent terrorism threats suggesting attacks with 'dirty bombs' containing combinations of radioactive isotopes with conventional explosives, has increased the interest in compounds that can protect from radiation injury. Histone deacetylase inhibitors represent a new class of compounds that can modulate the effects of radiation. Research with histone deacetylase inhibitors has largely focussed on the consequences of their ability to alter gene transcription via histone acetylation and on their properties as anti-cancer agents. They have been shown to cause cell cycle and growth arrest, differentiation and in certain cases apoptosis in cell cultures and in vivo. In addition to their intrinsic anti-cancer properties, numerous studies have demonstrated that histone deacetylase inhibitors can modulate cellular responses to other toxicity-inducing modalities including ionizing radiation. The consensus is that histone deacetylase inhibitors markedly enhance the sensitivity of cells to radiation by altering numerous molecular pathways. Intriguingly, a report has also shown that histone deacetylase inhibitors can reduce radiation induced acute and late skin damage using a well-established animal model of cutaneous radiation syndrome. Hence, there is an emerging interest in potential use of histone deacetylase inhibitors as radiation sensitizers or protectors. This review focuses on the different mechanisms by which histone deacetylase inhibitors modify cellular responses to ionizing radiation.
引用
收藏
页码:288 / 295
页数:8
相关论文
共 126 条
[1]   Cell cycle checkpoint signaling through the ATM and ATR kinases [J].
Abraham, RT .
GENES & DEVELOPMENT, 2001, 15 (17) :2177-2196
[2]   EFFECTS OF NUCLEOSIDE ANALOGS AND SODIUM-BUTYRATE ON RECOVERY FROM POTENTIALLY LETHAL X-RAY-DAMAGE IN HUMAN-COLON TUMOR-CELLS [J].
ARUNDEL, CM ;
LEITH, JT .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1987, 13 (04) :593-601
[3]   ENHANCEMENT OF RADIATION-INJURY IN HUMAN-COLON TUMOR-CELLS BY THE MATURATIONAL AGENT SODIUM-BUTYRATE (NAB) [J].
ARUNDEL, CM ;
GLICKSMAN, AS ;
LEITH, JT .
RADIATION RESEARCH, 1985, 104 (03) :443-448
[4]   Chemical agents that promote chromatin compaction radiosensitize tumour cells [J].
Biade, S ;
Stobbe, CC ;
Boyd, JT ;
Chapman, JD .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2001, 77 (10) :1033-1042
[5]   Cyclotherapy Protection of Normal Cells and Unshielding of Cancer Cells [J].
Blagosklonny, Mikhail V. ;
Darzynkiewicz, Zbigniew .
CELL CYCLE, 2002, 1 (06) :375-382
[6]   Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies [J].
Blaheta, RA ;
Michaelis, M ;
Driever, PH ;
Cinatl, J .
MEDICINAL RESEARCH REVIEWS, 2005, 25 (04) :383-397
[7]   Valproate in bipolar disorder: 2000 onwards [J].
Bowden, CL ;
Singh, V .
ACTA PSYCHIATRICA SCANDINAVICA, 2005, 111 :13-20
[8]   Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia [J].
Bug, G ;
Ritter, M ;
Wassmann, B ;
Schoch, C ;
Heinzel, T ;
Schwarz, K ;
Romanski, A ;
Kramer, OH ;
Kampfmann, M ;
Hoelzer, D ;
Neubauer, A ;
Ruthardt, M ;
Ottmann, OG .
CANCER, 2005, 104 (12) :2717-2725
[9]   Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid [J].
Camphausen, K ;
Cerna, D ;
Scott, T ;
Sproull, M ;
Burgan, WE ;
Cerra, MA ;
Fine, H ;
Tofilon, PJ .
INTERNATIONAL JOURNAL OF CANCER, 2005, 114 (03) :380-386
[10]   Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation [J].
Camphausen, K ;
Scott, T ;
Sproull, M ;
Tofilon, PJ .
CLINICAL CANCER RESEARCH, 2004, 10 (18) :6066-6071